Related Experiment Video

Updated: May 17, 2026

Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications
10:12

Quantitative Detection of DNA-Protein Crosslinks and Their Post-Translational Modifications

Published on: April 21, 2023

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

Junko Murai1, Shar-yin N Huang, Benu Brata Das

  • 1Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.

Cancer Research
|November 3, 2012
PubMed

Insights

PARP inhibitors trap PARP enzymes on DNA, acting as poisons rather than just catalytic inhibitors. This trapping mechanism is crucial for their antitumor effects and differs in potency among various inhibitors.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • Poly (ADP-ribose) polymerase (PARP) inhibitors are used in cancer therapy.
  • Their antitumor effects are thought to stem from blocking DNA repair.
  • The precise mechanism of action in cancer cells remains unclear.

Purpose of the Study:

  • To elucidate the mechanism of action of PARP inhibitors in cancer cells.
  • To investigate the role of PARP trapping in the cytotoxicity of these drugs.
  • To identify DNA repair pathways involved in resolving PARP-DNA complexes.

Main Methods:

  • Utilized genetically altered avian DT40 cell lines with specific DNA repair gene deletions.
  • Assessed the cytotoxic effects of PARP inhibitors.
  • Analyzed the formation and repair of PARP-DNA complexes.

Main Results:

  • PARP inhibitors trap PARP1 and PARP2 enzymes at sites of DNA damage.
  • Trapped PARP-DNA complexes are more cytotoxic than unrepaired single-strand breaks.
  • Inhibitor potency in trapping PARP varied significantly (niraparib > olaparib >> veliparib) and did not correlate with catalytic inhibition.
  • Homologous recombination, postreplication repair, Fanconi anemia pathway, polymerase β, and FEN1 are critical for repairing trapped PARP-DNA complexes.

Conclusions:

  • PARP inhibitors function partly as "poisons" that trap PARP on DNA, contributing to their antitumor activity.
  • The efficacy of PARP inhibitors is influenced by their ability to trap PARP, not solely their catalytic inhibition.
  • Understanding the repair pathways for PARP-DNA complexes is essential for optimizing PARP inhibitor therapy in cancer treatment.

More Related Videos

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Related Concept Videos

Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart, a...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...